Director of the Fisher Biomarker & Biorepository Laboratory @ Johns Hopkins Hospital
Associate Professor of Urology and Oncology @ Johns Hopkins Medical Institutions
Vice President & General Manager of R&D @ UroCor Inc.
West Virginia University School of Medicine
Robert W. Veltri, Ph.D. is Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine and studies the biomarkers for prostate and bladder cancer (http://urology.jhu.edu/ ). Currently, Dr. Veltri has collaborations with Case Western Reserve University biomedical engineering department and they are studying differentiating indolent vs. aggressive prostate cancer (PCa). He collaborates with PharmaSeq
Robert W. Veltri, Ph.D. is Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine and studies the biomarkers for prostate and bladder cancer (http://urology.jhu.edu/ ). Currently, Dr. Veltri has collaborations with Case Western Reserve University biomedical engineering department and they are studying differentiating indolent vs. aggressive prostate cancer (PCa). He collaborates with PharmaSeq Inc. that develops microtransponder-based (p-Chip) immunoassays to detect serum or urine biomarkers. PharmaSeq and Dr. Veltri have SBIR grants and contracts. He also has grants that include:Early Detection Research Network (EDRN) to characterize indolent vs. aggressive PCa; and two DOD grants one related to research on Active Surveillance monitoring in PCa and a second on Cancer Testes Antigens as biomarkers for aggressive PCa. Career experiences: 1) Dr. Veltri also served as Professor & Director of Otolaryngic Research and a member of the faculty of microbiology, surgery from 1968-80; 2) He managed R&D at a diagnostic company (1980-84), where he developed rapid FDA approved In Vitro diagnostic devices; 3) In 1985, he co-founded a therapeutics company (Theracel), which created nine patents covering several Aldol and Michael addition derivatives of Vitamin C; 4) at UroCor his R&D team (1991-2001) developed several products including UroScore, a urinalysis Stones 24-hour product, and a novel bladder cancer assay for p53 gene mutations, and the DD-23 BlCa detection urine biomarker and his R&D group patented several genes involved in PCa. Dr. Veltri has authored over 155 scientific publications and is either inventor or co-inventor on over twenty patents and two trademarks. .
Specialties: Research and Development, education, and training post-graduate students
Director of the Fisher Biomarker & Biorepository Laboratory @ I moved into a new modern laboratory January, 2009 From July 2005 to Present (10 years 6 months) Baltimore, Maryland AreaAssociate Professor of Urology and Oncology @ Associate Professor of Urology and Oncology and Director of the Fisher Biomarker Laboratory. From January 2002 to Present (14 years) Associate Professor of Urology and Oncology @ Directed research on prostate cancer molecular biomarkers and studied nuclear pleomorphism using computer assisted microscopy. Developed molecular biomarkers to characterized aggressive prostate cancer. Studying men undergoing active surveillance for prostate cancer to determine biomarkers, morphological or molecular, that can predict an aggressive phenotype. Trained undergraduate medical students, graduate fellows, and residents to conduct research on prostate cancer. From 2001 to Present (14 years) Vice President & General Manager of R&D @ I developed a team of scientists and technical staff to conduct research and development to develop service-based new morphological and molecular tools to detect, diagnose and prognose urologic cancers and benign diseases. Participated in State of Oklahoma science and technology programs to develop expand biotechnology expertise in the state. From 1991 to 2001 (10 years) Executive V.P. and Co-Founder @ The company developed chemical dervatives of Vitamin c based upon Aldol and Michael addition reactions that were useful for treatment of cancer, inflammation and infectious diseases. There were nine patents created and they were sold to Forest Laboratories in 1991. From January 1985 to December 1990 (6 years) Director of Research & Development @ In 1981-84 Dr. Veltri established an R&D team, which developed the first diagnostic application for liposomes and latex in slide a patented co-agglutination diagnostic kits for infectious and rheumatologic diseases. Three Class II FDA approved 510K products (Streptococcal Group A, Rheumatoid arthritis, and Infectious Mononucleosis) were transferred to manufacturing and released to market based. From January 1981 to August 1985 (4 years 8 months) Professor of Microbiology and Otolaryngology @ From 1969-80 Dr. Veltri served on the faculty of microbiology and surgery of WVU, where his applied research included virology, immunology, and cancer biomarkers. Dr. Veltri developed a fee for service clinical immunology and virology diagnostic testing service for the WVU hospital’s department of clinical pathology that generated about $100,000 in revenue by 1980. Teaching responsibilities included medical, dental, nursing and graduate level students in areas of microbiology, virology, and cancer biology. He also trained and served as advisor for six MS and six Ph.D. graduate students of microbiology during his tenure at WVU. A total of seventeen Medical, Dental, and Medical Technology students did research clerkships in Dr. Veltri’s laboratory during his tenure at WVU. He obtained more than $1.0 Million in extramural research funding while at WVU. From August 1969 to December 1980 (11 years 5 months)
Ph.D., Microbiology @ West Virginia University School of Medicine From 1964 to 1969 Ph.D., Microbiology @ West Virginia University School of Medicine From 1963 to 1969 BS in Biology and chemistry @ Youngstown State University From 1962 to 1964 Robert Veltri is skilled in: Cancer, Immunology, Oncology, Molecular Biology, Microscopy, Biotechnology, Infectious Diseases, In Vitro, Assay Development, Microbiology, Pathology, Proteomics, Genomics, Laboratory, Diagnostics
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension